You are here

Chris Drogemuller

Chris Drogemuller is the Principal Scientist of the Renal and Transplantation Immunology Laboratory and Affiliate Senior Lecturer with the University of Adelaide. He is responsible for the management of the RAH Renal Department laboratory which is made up of several research groups including Professor Toby Coates (Islet Transplantation, Dendritic Cell Biology, Cell Therapy and Transplant Immunology), Dr Rob Carroll (Transplant Immunology and T Cell Biology (Tregs)), Dr Chen Au Peh (Vasculitis) and Dr Shilpa Jesudason (Transplant Immunology and Dendritic Cell and T Cell Biology).

He has been the Senior Scientist on the South Australian and Northern Territory Islet Program (SANTIP) since 2007 and recently completed a clinical trial of islet transplantation in type 1 diabetics published in the American Journal of Transplantation. Prior to this he worked four years in America as the senior scientist (Molecular and Cellular Biology) within a clinical stage gene therapy company, two years in a cancer gene discovery project at the Hanson Institute (SA) and five years in clinical pharmacology at the Flinders Medical Centre (SA).

Qualifications

1995 Bachelor of Biotechnology (Honours). Flinders University of South Australia, Bedford Park, South Australia.
1995 Certificate course in the Care and Welfare of Experimental Animals. Flinders University of South Australia.
1997 Radiation Safety Course. University of Adelaide, Adelaide, South Australia.
2005 Business Basics for Scientists. University of Florida, Gainesville, FL, USA.

Awards & Achievements

2011 TSANZ Travel Award (competitive application). To travel and present research at the 13th International IPITA conference in Prague, Czech Republic.
2008 JDRF Travel Grant (competitive application). To travel and present research at the 22nd International TTS conference in Sydney, Australia.
1998

Ian Potter Foundation Institutional Travel Award (competitive application). To travel and present research at the 5th International ISSX conference in Cairns, Queensland.

Teaching Interests

  • Supervisor (PhD)
  • PhD Students Completed; Ms Amy Hughes, Ms Mariea Dency-Bosco
  • PhD Students Current; Mr Bron Letts.
  • Supervisor (Hons)
  • Honours Students Completed; Ms Amanda Kupke (1st Class), Frederick Chia (1st Class) and Ahmad Rosli (1st Class)
Publications: 

P J O’Connell, DJ Holmes-Walker, D Goodman, W J Hawthorne, T Loudovaris, J E Gunton, H E Thomas, S T Grey, C J Drogemuller, G M Ward, D J Torpy, P T Coates, T W Kay, On behalf of the Australian Islet Transplant Consortium*. Multicenter Australian Trial of Islet Transplantation: Improving Accessibility and Outcomes. American Journal of Transplantation. 2013 May 13. doi: 10.1111/ajt.12250. [Epub ahead of print].

Hughes, A., Mohanasundaram, D., Kireta, S., Jessup, C.F., Drogemuller, C.J. and P.T.H. Coates. Insulin-like growth factor-II (IGF-II) prevents pro-inflammatory cytokine induced apoptosis and significantly improves islet survival post-transplantation. Transplantation. 95(5): (2013).

Penko, D., Mohanasundaram, D., Sen, S., Drogemuller, C., Mee, C., Bonder, C.S., Coates, P.T. and Jessup, C.F. Incorporation of endothelial progenitor cells into mosaic pseudoislets. Islets. 3(3): 73-9 (2011).

Mohanasundaram, D.M., Drogemuller, C., Brealey, J., Jessup, C.F., Milner, C., Murgia, C., Lang, C.J., Milton, A., Zalewski, P.D., Russ, G.R. and Coates, P.T. Ultrastructural analysis, zinc transporters, glucose transporters and hormones expression in new world primate (Callithrix jacchus) and human pancreatic islets. Gen. Comp. Endocrinol. 1:174(2):71-9 (2011).

Hughes, A., Jessup, C., Drogemuller, C., Mohanasundaram, D., Milner, C., Rojas, D., Russ, G.R. and Coates, P.T. Gene therapy to improve pancreatic islet transplantation for type 1 diabetes mellitus. Curr. Diabetes Rev. 6(5):274-284 (2010).

Bosco, M.D., Mohanasundaram, D.M., Drogemuller, C.J., Lang, C.J., Zalewski, P.D. and Coates, P.T. Zinc and zinc transporter regulation in pancreatic islets and the potential role of zinc in islet transplantation. Rev. Diabet. Stud. 7(4): 263-274 (2010).

Gamble J.R., Xia P., Hahn C.N., Drew J.J., Drogemuller C.J., Brown D., Vadas M.A. Phenoxodiol, an experimental anticancer drug, shows potent anti-angiogenic properties in addition to its anti-tumour effects. Int. J. Cancer. 118(10):2412-20 (2006).

Hahn, C.N., Su, Z.J., Drogemuller, C.J., Tsykin, A., Waterman, S.R, Brautigan, P.J., Yu, S., Kremmidiotis, G., Gardner, A., Solomon, P.J., Goodall, G.J., Vadas, M.A. and Gamble, J.R. Expression profiling reveals functionally important genes and co-ordinately regulated signaling pathway genes during in vitro angiogenesis. Physiol. Genomics. 22(1): 57-69 (2005).

Drogemuller, C.J., Nunthasomboon, S. and Knights, K.M. Nafenopin-, Ciprofibroyl-, and Palmitoyl-CoA Conjugation in Vitro: Kinetic and Molecular Characterisation of Marmoset Liver Microsomes and Expressed MLCL1. Arch. Biochem. Biophys. 396(1): 56-64 (2001).

Knights, K.M. and Drogemuller, C.J. Xenobiotic-CoA ligases: Kinetic and molecular characterisation. [Invited Review]. Current Drug Metabolism. 1(1): 49-66 (2000).

Sallustio, B.C., Nunthasomboon, S., Drogemuller, C.J. and Knights, K.M. In vitro covalent binding of nafenopin-CoA to human liver proteins. Toxicol. App. Pharmacol. 163: 176-182 (2000).